Search

Your search keyword '"Algera, M.D."' showing total 7 results
Start Over Author "Algera, M.D."
7 results on '"Algera, M.D."'

1. Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit

Author

Kruse, A.J., Yigit, R., Engelen, M.J.A., Nooij, L.S., Mens, J.W.M., de Jong, M.A.A., Haverkort, M.A.D., van der Aa, M., Diepstraten, J., van Ham, M.A.P.C., Smedts, H.P.M., Reesink, N., Gaarenstroom, K.N., Vencken, P.M.L.H., Boll, D., Fons, G., Baalbergen, A., van Dorst, E.B.L., Roes, E.M., Nagel, H.T.C., van Ginkel, A., de Waard, J., Hofman, L.N., Algera, M.D., van Driel, W.J., Slangen, B.F.M., Wouters, M.W.J.M., and Kruitwagen, R.F.P.M.

Published
2024
Full Text
View/download PDF

3. Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit

Author

Algera, M.D., primary, van Driel, W.J., additional, Slangen, B.F.M., additional, Wouters, M.W.J.M., additional, Kruitwagen, R.F.P.M., additional, Kruse, A.J., additional, Yigit, R., additional, Engelen, M.J.A., additional, Nooij, L.S., additional, Mens, J.W.M., additional, de Jong, M.A.A., additional, Haverkort, M.A.D., additional, van der Aa, M., additional, Diepstraten, J., additional, van Ham, M.A.P.C., additional, Smedts, H.P.M., additional, Reesink, N., additional, Gaarenstroom, K.N., additional, Vencken, P.M.L.H., additional, Boll, D., additional, Fons, G., additional, Baalbergen, A., additional, van Dorst, E.B.L., additional, Roes, E.M., additional, Nagel, H.T.C., additional, van Ginkel, A., additional, de Waard, J., additional, and Hofman, L.N., additional

Published
2024
Full Text
View/download PDF

5. Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery

Author

Algera, M.D., Driel, W.J. van, Slangen, B.F.M., Kruitwagen, R.F.P.M., Wouters, M.W.J.M., Baalbergen, A., Cate, A.D. ten, Aalders, A.L., Kolk, A. van der, Kruse, A.J., Haaften-deJong, A.M.L.D. van, Swaluw, A.M.G. van de, Visschers, B.A.J.T., Buis, C.C.N., Gerestein, C.G., Smeets, C.M.W.H., Boll, D., Laar, R. van de, Ngo, D.H., Davelaar, E., Ooms, E.A., Dorst, E.B.L. van, Schmeink, C.E., Es, E.J.M. van, Roes, E.M., Cate, F.A. ten, Rijcken, F.E.M., Rosier-van Dunne, F.M.R., Fons, G., Jansen, G.H., Verhoeve, H.R., Nagel, H.T.C., Keizer, H.H., Smedts, H.P.M., Ebisch, I.M.W., Lande, J. van de, Louwers, J.A., Briet, J., Waard, J. de, Diepstraten, J., Vollebergh, J.H.A., Avoort, I.A.M. van der, Dijk, J.E.W. van, Lange, J.G., Mens, J.W.M., Gaarenstroom, K.N., Overmars, K., Vries, L.C. de, Hofman, L.N., Bartelink, L.R., Huisman, M.A., Verbruggen, M.B., Vos, M.C., Huisman, M., Kleppe, M., Hende, M. van den, Aa, M. van der, Wust, M.D., Baas, M.I., Engelen, M.J.A., Scheers, E.C.A.H., Moonen-Delarue, M.W.G., Tjiong, M.Y., Leffers, N., Reesink, N., Timmers, P.J., Kolk, P., Vencken, P.M.L.H., Yigit, R., Smit, R.A., Westenberg, S.M., Coppus, S.F.P.J., Stam, T.C., Schukken, T.K., Baal, W.M. van, Minderhoud-Bassie, W., Plas-Koning, Y.W.C.M. van der, Ham, M.A.P.C. van, Targeted Gynaecologic Oncology (TARGON), Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), Epidemiology and Data Science, APH - Aging & Later Life, APH - Societal Participation & Health, Gynecological Oncology, Radiotherapy, Obstetrics and Gynaecology, CCA - Cancer Treatment and Quality of Life, Obstetrie & Gynaecologie, RS: GROW - R2 - Basic and Translational Cancer Biology, MUMC+: MA Medische Staf Obstetrie Gynaecologie (9), MUMC+: MA Obstetrie Gynaecologie (3), MUMC+: Vrouw Moeder en Kind Centrum (3), MUMC+: MA Arts Assistenten Obstetrie Gynaecologie (9), and MUMC+: MA Toegelatenen Obstetrie Gynaecologie (9)

Subjects
Ovarian Neoplasms, Pandemic, Surgical volume, Vulvar cancer, Obstetrics and Gynecology, COVID-19, Uterine Cervical Neoplasms, Postoperative outcomes, Endometrial Neoplasms, Perioperative care processes, Cohort Studies, Oncology, SDG 3 - Good Health and Well-being, Endometrial cancer, Gynecological oncology, Ovarian cancer, Cervical cancer, Humans, Impact COVID-19, Female, Pandemics
Abstract

Objective. The COVID-19-pandemic caused drastic healthcare changes worldwide. To date, the impact of these changes on gynecological cancer healthcare is relatively unknown. This study aimed to assess the impact of the COVID-19-pandemic on surgical gynecological-oncology healthcare. Methods. This population-based cohort study included all surgical procedures with curative intent for gynecological malignancies, registered in the Dutch Gynecological Oncology Audit, in 2018-2020. Four periods were identified based on COVID-19 hospital admission rates: 'Pre-COVID-19', 'Firstwave', 'Interimperiod', and'Second wave'. Surgical volume, perioperative care processes, and postoperative outcomes from 2020 were compared with 2018-2019. Results. A total of 11,488 surgical procedureswere analyzed. For cervical cancer, surgical volume decreased by 17.2% in 2020 compared to 2018-2019 (mean 2018-2019: n= 542.5, 2020: n= 449). At nadir (interimperiod), only 51% of the expected cervical cancer procedures were performed. For ovarian, vulvar, and endometrial cancer, volumes remained stable. Patients with advanced-stage ovarian cancer more frequently received neoadjuvant chemotherapy in 2020 compared to 2018-2019 (67.7% (n = 432) vs. 61.8% (n = 783), p = 0.011). Median time to first treatmentwas significantly shorter in all four malignancies in 2020. For vulvar and endometrial cancer, the length of hospital staywas significantly shorter in 2020. No significant differences in complicated course and 30-day-mortality were observed. Conclusions. The COVID-19-pandemic impacted surgical gynecological-oncology healthcare: in 2020, surgical volume for cervical cancer dropped considerably, waiting time was significantly shorter for all malignancies, while neoadjuvant chemotherapy administration for advanced-stage ovarian cancer increased. The safety of perioperative healthcare was not negatively impacted by the pandemic, as complications and 30-day-mortality remained stable. (C) 2022 The Authors. Published by Elsevier Inc.

Published
2022

6. Case-mix adjustment to compare hospital performances regarding complications after cytoreductive surgery for ovarian cancer: a nationwide population-based study.

Author

Algera, M.D., Baldewpersad Tewarie, N.M.S., Driel, W.J. van, Ham, M.A.P.C. van, Slangen, B.F.M., Kruitwagen, R.F.P.M., Wouters, M.W., Algera, M.D., Baldewpersad Tewarie, N.M.S., Driel, W.J. van, Ham, M.A.P.C. van, Slangen, B.F.M., Kruitwagen, R.F.P.M., and Wouters, M.W.

Abstract

Item does not contain fulltext, OBJECTIVE: Complication rates after cytoreductive surgery are important quality indicators for hospitals that treat patients with advanced-stage ovarian cancer. Case-mix factors are patient and tumor characteristics that may influence hospital outcomes such as the complication rates. Currently, no case-mix adjustment model exists for complications after cytoreductive surgery; therefore, it is unclear whether hospitals are being compared correctly. This study aims to develop the first case-mix adjustment model for complications after surgery for advanced-stage ovarian cancer, enabling an accurate comparison between hospitals. METHODS: This population-based study included all patients undergoing cytoreductive surgery for advanced-stage ovarian cancer registered in the Netherlands in 2017-2019. Case-mix variables were identified and assessed using logistic regressions. The primary outcome was the composite outcome measure 'complicated course'. Patients had a complicated course when at least one of the following criteria were met: (1) any complication combined with a prolonged length of hospital stay; (2) complication requiring reintervention; (3) any complication with a prolonged length of stay in the intensive care unit; or (4) 30-day mortality or in-hospital mortality during admission following surgery. Inter-hospital variation was analyzed using univariable and multivariable logistic regressions and visualized using funnel plots. RESULTS: A total of 1822 patients were included, of which 10.7% (n=195) had a complicated course. Comorbidity and tumor stage had a significant impact on complicated course rates in multivariable logistic regression. Inter-hospital variation was not significant for case-mix factors. Complicated course rates ranged between 2.2% and 29.1%, and case-mix adjusted observed/expected ratios ranged from 0.20 to 2.67 between hospitals. Three hospitals performed outside the confidence intervals for complicated course rates. These hospitals remained o

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results